Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00685568
Other study ID # ID02-090
Secondary ID MDA-ID-02090CDR0
Status Completed
Phase Phase 1
First received
Last updated
Start date November 21, 2002
Est. completion date April 21, 2006

Study information

Verified date November 2018
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of celecoxib may keep polyps and colorectal cancer from forming in patients with familial adenomatous polyposis.

PURPOSE: This randomized phase I trial is studying the side effects and best dose of celecoxib in treating young patients with a genetic predisposition for familial adenomatous polyposis.


Description:

OBJECTIVES:

Primary

- Determine the safety and toxicity of celecoxib in pediatric patients with genotype-positive familial adenomatous polyposis.

Secondary

- Determine the aberrant crypt foci (ACF) and adenoma burden in the entire colorectum of these patients.

- Eliminate the learning curve in a phase II/III trial (reproducibility of endoscopic techniques, tolerability of procedure).

- Compare sedation strategies based on local standards (monitored anesthesia care vs conscious sedation).

- Validate the ACF scoring technique.

- Establish the short-term (3 month) impact of celecoxib on ACF count in order to determine appropriateness of ACF as a pathologic endpoint in a phase II/III trial.

OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.

- Arm I: Patients receive oral celecoxib twice daily for 3 months in the absence of disease progression or unacceptable toxicity.

- Arm II: Patients receive oral placebo twice daily for 3 months in the absence of disease progression or unacceptable toxicity.

Patients undergo colonoscopy at baseline and at 3 months. Patients also complete psychosocial questionnaires at baseline.

Blood samples are collected at baseline to assess the influence of polymorphisms (CYP2C9, uridine diphosphate (UDP)-glucuronosyl transferase, A6, glutathione S-transferase [GST] M1, and Glutathione S-transferase (GST) theta 1 (GSTT1)) on age of onset of phenotype or number of colorectal polyps. Plasma drug trough levels are assessed at baseline, 1 month, and 3 months.

After completion of study treatment, patients are followed periodically for up to 2 months.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date April 21, 2006
Est. primary completion date April 21, 2006
Accepts healthy volunteers No
Gender All
Age group 10 Years to 14 Years
Eligibility DISEASE CHARACTERISTICS:

- Diagnosis of familial adenomatous polyposis (FAP) based on genetic predisposition testing

- Genotype-positive FAP (pathologic Adenomatous polyposis coli (APC) mutation)

- No attenuated FAP genotype, defined by any of the following:

- Mutation at the 5' end of APC and exon 4

- Exon 9-associated phenotypes

- 3' region mutations

- Has an intact colon

- No requirement for colectomy

- Parent(s) do not desire colectomy (regardless of adenoma burden)

- Colorectal adenoma burden as assessed by baseline colonoscopy

- No diagnosis of severe dysplasia or greater

- No more than 10 adenomas = 1 cm

- No more than 100 adenomas of any size

- No evidence of anemia (hematocrit < 33%)

- No new diagnosis of carcinoma

PATIENT CHARACTERISTICS:

- White Blood Count (WBC) > 3,000/µL

- Platelet count > 100,000/µL

- Hemoglobin > 10.0 g/dL

- Aspartate aminotransferase/alanine aminotransferase (AST/ALT) < 1.5 times upper limit of normal (ULN)

- Alkaline phosphatase < 1.5 times ULN

- Total bilirubin < 1.5 times ULN

- Creatinine < 1.5 times ULN

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No history of hypersensitivity to COX-2 inhibitors, sulfonamides, NSAIDs, or salicylates

- No history of peptic ulcer disease

- No significant medical or psychiatric problem that, in the opinion of the principal investigator, would make the patient a poor candidate for the study

- No other unacceptable clinical risk (e.g., previously unknown bleeding diatheses)

- No invasive carcinoma within the past 5 years

PRIOR CONCURRENT THERAPY:

- More than 3 months since prior investigational agent

- More than 6 months since prior chemotherapy

- No prior radiotherapy to the pelvis

- At least 3 months since prior NSAIDs (at any dose) at a frequency of = 3 times/week

- At least 1 month since prior NSAIDs (at any dose) at a frequency of < 3 times/week

- At least 1 month since prior nasal steroids

- Concurrent Nonsteroidal Antiinflammatory Drugs (NSAIDs) allowed provided they are administered = 5 times per month

- Concurrent orally inhaled steroids allowed provided they are administered for = 4 weeks over a 6-month period

- Concurrent oral or intravenous (IV) corticosteroids allowed provided they are administered for = 2 consecutive weeks over a 6-month period

- Concurrent proton pump inhibitors to treat gastric reflux allowed

- No concurrent nasal steroids except mometasone (Nasonex)

- No concurrent fluconazole, lithium, or adrenocorticosteroids

Study Design


Intervention

Drug:
celecoxib
Orally, twice daily for 3 months; 50 mg tablets. Celecoxib escalating doses starting at 4 mg/kg/day.
Other:
placebo
Orally, twice daily for 3 months

Locations

Country Name City State
United States Cleveland Clinic Taussig Cancer Center Cleveland Ohio
United States M. D. Anderson Cancer Center at University of Texas Houston Texas
United States Texas Children's Hospital Houston Texas
United States University of Texas Medical School at Houston Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Lynch PM, Ayers GD, Hawk E, Richmond E, Eagle C, Woloj M, Church J, Hasson H, Patterson S, Half E, Burke CA. The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am J Gastroenterol. 2010 Jun;105(6):1437-43. doi: 10.1038/aj — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Toxicity 3 months
Secondary Aberrant crypt foci (ACF) and adenoma burden in the entire colorectum 3 months
Secondary Elimination of the learning curve in a phase II/III trial 3 months
Secondary Comparison of sedation strategies based on local standards 3 months
Secondary Validation of technique for scoring ACFs 3 months
Secondary Short-term (3 month) impact of celecoxib on ACF count 3 months
Secondary Adherence 3 months
Secondary Influence of polymorphisms on age of onset of phenotype or on the number of colorectal polyps 3 months
Secondary Feasibility of psychosocial questionnaires 3 months
Secondary Pharmacokinetics (plasma drug trough concentrations) 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A